搜索
再生元制药
REGN添加自选
654.270USD
+29.550+4.73%
收盘 07/02, 13:00（美东）报价延迟15分钟
68.70B总市值
15.40市盈率 TTM
关于 再生元制药 公司
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
再生元制药简介
公司代码REGN
公司名称Regeneron Pharmaceuticals Inc
上市日期Apr 02, 1991
CEOSchleifer (Leonard S)
员工数量15106
证券类型Ordinary Share
年结日Apr 02
公司地址777 Old Saw Mill River Road
城市TARRYTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编10591
电话17813705000
网址https://www.regeneron.com/
公司代码REGN
上市日期Apr 02, 1991
CEOSchleifer (Leonard S)
再生元制药公司高管
名称
名称/职务
职务
持股
持股变动
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.80K
+0.07%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.42K
-0.57%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.49K
+0.82%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.78K
+0.04%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
常见问题
再生元制药的前五大股东是谁？
再生元制药 的前五大股东如下：Dr. George D. Yancopoulos, M.D., Ph.D
有多少机构持有再生元制药(REGN)的股份？
截至2026Q1，共有2806家机构持有再生元制药的股份，合计持有的股份价值约为94.67M，占公司总股份的91.89%。与2025Q4相比，机构持股有所增加，增幅为-1673066.00。
哪个业务部门对再生元制药的收入贡献最大？
在2026Q1，Sanofi业务部门对再生元制药的收入贡献最大，创收5.88B，占总收入的41.02%。